CTOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Bramalea Denistry

Bramalea Denistry is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Decade of Discovery

Decade of Discovery is a major research initiative led by the Minnesota Partnership for Biotechnology and Medical Genomics focused on preventing, optimally treating and ultimately curing diabetes.

CanReg

CanReg, Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Joimax USA

Joimax USA is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PharmaCannis

PharmaCannis is a medical cannabis provider under the Illinois, and New York Compassionate Use of Medical Cannabis Pilot Program Act. We take pride in the professionalism, compassion, security and privacy we provide to patients and caregivers. PharmaCannis strives to enhance the lives of patients through quality products and impeccable service, while maintaining a clean, safe, and peaceful environment. We seek to improve our community`s understanding of medical marijuana and its effects through reliance on science-based research. Our staff is friendly, knowledgeable and compassionate. We will always maintain full, accurate, and complete compliance with Illinois, and New York law and federal law enforcement priorities.